Customers often mention the noticeable impact on their energy levels and metabolism
One study found that, of cats investigated for gastrointestinal disease, 9 of 33 cats (27%) had no pathology recognized proximal to the jejunum (i.e., the effective length of diagnostic endoscopes would have precluded diagnosis), and other organs were affected in 9 of 10 cats with inflammatory bowel diseases and 7 of 8 cats with intestinal small cell lymphoma
Disease aside, its a ticket to better health and longevity
That's because the drug works by targeting three gut hormones, including one called glucagon, which increases energy expenditure
This ensures there is no air trapped in the needle and that the device is working correctly
Common outcomes include: Gradual and sustainable weight loss Noticeable appetite reduction Improved portion control Fewer cravings Better metabolic stability Oral GLP-1 therapy is not one-size-fits-all